Top

Published in:

01-03-2009 | Original Paper

Common genetic polymorphisms of AURKA and prostate cancer risk

Authors: Elisabeth Feik, Andreas Baierl, Stephan Madersbacher, Georg Schatzl, Agnes Maj-Hes, Richard Berges, Michael Micksche, Andrea Gsur

Published in: Cancer Causes & Control | Issue 2/2009

Abstract

Purpose

AURKA is a centrosome-associated serine/threonine kinase involved in mitotic chromosomal segregation. The AURKA gene is located on chromosome 20q13, also known as HPC20 prostate cancer susceptibility locus. Therefore, we investigated in this Caucasian case–control study two single nucleotide polymorphisms (SNPs) of the AURKA gene, rs8173 located in the 3′-untranslated region (G1891C) and rs2273535 in exon 5 (Phe31Ile), and their association with prostate cancer risk.

Methods

DNA was extracted from peripheral blood of 824 prostate cancer patients and 1,081 control patients with benign prostatic hyperplasia (BPH). Genotypes were determined using 5′-nuclease TaqMan assays. Multiple logistic regressions were performed to calculate odds ratios (OR) and confidence intervals (CI) and to adjust for confounders.

Results

The odds ratios calculated relative to the wild-type were for the homozygous polymorphic genotypes 1.11 (95% CI = 0.70–1.76) for rs8173 and 1.32 (95% CI = 0.76–2.31) for rs2273535, respectively. Stratified analyses according to Gleason score showed also no statistically significant association for the investigated polymorphisms and prostate cancer risk.

Conclusions

The two investigated SNPs in AURKA were not found to be associated with prostate cancer risk. Other common SNPs of AURKA should be investigated in further studies because of its location on a prostate cancer susceptibility locus.

Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ (2001) Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 61(5):2212–2219PubMed

Bischoff JR, Anderson L, Zhu Y et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052–3065. doi:10.1093/emboj/17.11.3052 PubMedCrossRef

Zhou H, Kuang J, Zhong L et al (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189–193. doi:10.1038/2496 PubMedCrossRef

Sakakura C, Hagiwara A, Yasuoka R et al (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84(6):824–831. doi:10.1054/bjoc.2000.1684 PubMedCrossRef

Li D, Zhu J, Firozi PF et al (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9(3):991–997PubMed

Moreno-Bueno G, Sanchez-Estevez C, Cassia R et al (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63(18):5697–5702PubMed

Bar-Shira A, Pinthus JH, Rozovsky U et al (2002) Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res 62(23):6803–6807PubMed

Buschhorn HM, Klein RR, Chambers SM et al (2005) Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 64(4):341–346. doi:10.1002/pros.20247 PubMedCrossRef

Berry R, Schroeder JJ, French AJ et al (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67(1):82–91. doi:10.1086/302994 PubMedCrossRef

10.

Lee EC, Frolov A, Li R, Ayala G, Greenberg NM (2006) Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 66(10):4996–5002. doi:10.1158/0008-5472.CAN-05-2796 PubMedCrossRef

11.

Ewart-Toland A, Briassouli P, de Koning JP et al (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34(4):403–412. doi:10.1038/ng1220 PubMedCrossRef

12.

R development core team (2008) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Wien. URL: http://www.R-project.org

13.

Miao X, Sun T, Wang Y, Zhang X, Tan W, Lin D (2004) Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 64(8):2680–2683. doi:10.1158/0008-5472.CAN-04-0651 PubMedCrossRef

14.

Egan KM, Newcomb PA, Ambrosone CB et al (2004) STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 25(11):2149–2153. doi:10.1093/carcin/bgh231 PubMedCrossRef

15.

Sun T, Miao X, Wang J et al (2004) Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 25(11):2225–2230. doi:10.1093/carcin/bgh244 PubMedCrossRef

16.

Dicioccio RA, Song H, Waterfall C et al (2004) STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(10):1589–1594PubMed

17.

Lo YL, Yu JC, Chen ST et al (2005) Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 115(2):276–283. doi:10.1002/ijc.20855 PubMedCrossRef

18.

Kimura MT, Mori T, Conroy J et al (2005) Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res 65(9):3548–3554. doi:10.1158/0008-5472.CAN-04-2149 PubMedCrossRef

19.

Webb EL, Rudd MF, Houlston RS (2006) Case–control, kin-cohort and meta-analyses provide no support for STK15 F31I as a low penetrance colorectal cancer allele. Br J Cancer 95(8):1047–1049. doi:10.1038/sj.bjc.6603382 PubMedCrossRef

20.

Ju H, Cho H, Kim YS et al (2006) Functional polymorphism 57Val>Ile of aurora kinase A associated with increased risk of gastric cancer progression. Cancer Lett 242(2):273–279. doi:10.1016/j.canlet.2005.11.015 PubMedCrossRef

21.

Fletcher O, Johnson N, Palles C et al (2006) Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 98(14):1014–1018PubMedCrossRef

22.

Cox DG, Hankinson SE, Hunter DJ (2006) Polymorphisms of the AURKA (STK15/Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes Control 17(1):81–83. doi:10.1007/s10552-005-0429-9 PubMedCrossRef

23.

Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X (2007) Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28(2):350–355. doi:10.1093/carcin/bgl149 PubMedCrossRef

24.

Dai Q, Cai QY, Shu XO et al (2004) Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13(12):2065–2070PubMed

25.

Ewart-Toland A, Dai Q, Gao YT et al (2005) Aurora-A/STK15 T + 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26(8):1368–1373. doi:10.1093/carcin/bgi085 PubMedCrossRef

26.

Chan JM, Stampfer MJ, Ma J et al (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14):1099–1106PubMed

27.

Gsur A, Preyer M, Haidinger G et al (2002) Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23(10):1647–1651. doi:10.1093/carcin/23.10.1647 PubMedCrossRef

28.

Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474–479PubMed

Title: Common genetic polymorphisms of AURKA and prostate cancer risk
Authors: Elisabeth Feik
Andreas Baierl
Stephan Madersbacher
Georg Schatzl
Agnes Maj-Hes
Richard Berges
Michael Micksche
Andrea Gsur
Publication date: 01-03-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 2/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9227-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

Season of interview and self-report of summer sun protection behaviors

Energy balance, early life body size, and plasma prolactin levels in postmenopausal women

The impact of physical activity on all-cause mortality in men and women after a cancer diagnosis

Childhood stature and adult cancer risk: the Boyd Orr cohort

Infectious exposure in the first year of life and risk of central nervous system tumors in children: analysis of day care, social contact, and overcrowding

Pregnancy weight gain is not associated with maternal or mixed umbilical cord estrogen and androgen concentrations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer